Advancing Preclinical Drug Development for Ocular Disease with Vascularized 3D Tumour Models
- Asees Kaur
- Jul 31
- 2 min read
Victoria, July 2025—VoxCell BioInnovation is proud to announce a strategic partnership with Altasciences, to advance early-stage drug development through the integration of VoxCell’s 3D bioprinted vascularized tumour models into Altasciences’ discovery and preclinical workflows.
This collaboration will initially focus on ocular disease, with plans to expand into additional therapeutic areas. By combining Altasciences’ comprehensive early-phase drug development expertise with VoxCell’s fully perfusable, human-relevant 3D bioprinted vascularized tumour models, the partnership aims to reduce R&D timelines, improve the success rate of investigational therapies, and support smarter, faster decisions in early-stage drug development.
VoxCell’s proprietary bioprinted tissues are engineered to closely mimic the complexity of human biology, including tumour architecture and microvascular networks, offering researchers a more physiologically relevant platform for evaluating drug efficacy and safety in the earliest stages of development.
Our mission has always been to make drug screening more human-relevant and predictive. Altasciences shares this forward-thinking approach, and we’re excited to work together to support pharmaceutical and biotech companies in making faster, more informed decisions.
Dr. Karolina Valente, CEO of VoxCell BioInnovation
Supporting the Shift Toward Non-Animal Testing
This partnership reflects a shared commitment to the 3Rs (Replacement, Reduction, and Refinement) and the broader global movement toward New Approach Methodologies (NAMs): innovative, non-animal tools that better represent human biology. As the FDA continues to move away from animal testing, human-relevant platforms like 3D vascularized models using patient-derived cells are becoming essential. These next-generation models elevate ethical standards in research, enhance translational relevance, and align with the FDA’s roadmap for improving drug development through more predictive, human-based systems.
About VoxCell BioInnovation
VoxCell BioInnovation is a leading provider of next-generation in vitro models, powered by our 3D bioprinted, vascularized tissue technology. Our ready-to-perfuse models closely replicate human biology with in vivo–like microvascular networks, enabling nutrient and oxygen delivery, systemic drug distribution, and more predictive therapeutic responses. VoxCell’s end-to-end solution offers researchers and pharmaceutical companies a scalable, ethical alternative to animal testing. Our mission is to reduce reliance on animal models, accelerate preclinical development, and advance more effective therapies for patients.
Want to learn more or collaborate?
Visit our website, connect with us on LinkedIn, or email us at hello@voxcellbio.com.
